After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
Source：MarketWatch
友情提醒：请广大读者理性看待市场信息，切实提高风险意识。站内所有内容仅系市场信息或相关方观点，不构成任何形式投资建议。